BRASKEM S.A.
Corporate Taxpayer ID (C.N.P.J.) No. 42.150.391/0001-70
State Registration (NIRE) 29300006939
Publicly-held company

MATERIAL FACT

Braskem S.A. ("Braskem" or the "Company") (B3 Tickers: BRKM3, BRKM5, and BRKM6; NYSE: BAK; LATIBEX: XBRK), following up on the Material Facts disclosed on August 24, 2026 regarding the filing of a request for out-of-court reorganization by the Company and certain of its subsidiaries (the "Extrajudicial Reorganization") and October 24, 2026, hereby notifies its shareholders and the market in general that Braskem (with the support of its main shareholders, Shine I Fundo de Investimento em Participações de Responsabilidade Limitada and Petróleo Brasileiro S.A. – Petrobras) has reached an agreement in principle on key commercial terms and conditions of the Updated Plan ("Agreed Principles") with a steering committee of a group of creditors that collectively represents a majority of claims subject to the Extrajudicial Reorganization plan (the ("ER Plan").

Braskem and its financial creditors are currently negotiating the definitive terms and documentation of the Updated Plan reflecting the Agreed Principles and its implementation mechanics, with the aim to submit such Updated Plan to the ER Court in the coming weeks. In order to achieve this, Braskem filed before the ER Court a request to extend the deadline to submit the Updated Plan by 20 Business Days and such extension request was supported by financial creditors of Braskem representing the majority of the subject claims under the ER Plan.

The Agreed Principles do not constitute a preliminary contract for purposes of any Law and are not binding upon or enforceable against Braskem, the other debtors under the ER Plan, its main shareholders or any of Braskem's financial creditors. The terms and conditions that will be set forth in the Updated Plan remain subject to the negotiation and execution of definitive documentation, and will be contingent upon the applicable corporate governance approvals of Braskem, the other debtors under the ER Plan, its main shareholders and Braskem's financial creditors and shall not be binding upon or enforceable against the Company, the other debtors and creditors bound by the ER Plan, unless and until such terms and conditions are set forth in the Updated Plan that is duly confirmed by the applicable ER Court and in the definitive binding agreements implementing such terms and conditions.

In addition, Braskem hereby notifies that it has provided the Investors with the following non-public information related to Braskem and its subsidiaries ("Shared Information"), in the context of negotiations regarding updates to ER Plan:

1. Discussion materials from Braskem with updated cash flow projections and other financial and operational information, delivered by Braskem on October 30, 2026 pursuant to the terms of the Plan filed on August 24; and
2. Agreed Principles.

Pursuant to the confidentiality agreements entered into in November 2026 between Braskem and the Investors (collectively, the "Confidentiality Agreements"), Braskem has agreed to publicly disclose the Shared Information after the expiration of the term set forth in the Confidentiality Agreements. The Shared Information is attached hereto and is provided to fulfill Braskem's obligations under the Confidentiality Agreements and in accordance with applicable legal regulations.

The Shared Information contains projections regarding prices, sales volumes, feedstock consumption and supply, costs, production and utilization rates, as well as Braskem's financial indicators, through 2035. The projections presented are hypothetical data and forecasts that reflect the current expectations of Braskem's management and should not be construed as guarantees or promises of performance, being subject to risks and uncertainties associated with the economic, regulatory, and competitive conditions of the markets in which Braskem operates, and may therefore differ materially from the figures and results actually recorded by Braskem.

The Company clarifies that the projections contained in the Shared Information by Braskem should not be considered guidance and were prepared in the context of the Extrajudicial Reorganization.

The Company will keep the market informed of any material developments regarding this matter, in compliance with applicable laws.

Additional information may be obtained from the Investor Relations Department by calling (11) 3576-9531 or by emailing braskem-ri@braskem.com.br.

São Paulo, November 23, 2026

Carlos Augusto Machado Pereira de Almeida Brandão

Chief Financial and Investor Relations Officer

Braskem S.A.

FORWARD-LOOKING STATEMENTS

This Material Fact may contain forward-looking statements. These statements are not historical facts, but rather are based on the current view and estimates of the Company's management regarding future economic and other circumstances, industry conditions, financial performance and results, including any potential or projected impact regarding the geological event in Alagoas and related legal procedures on the Company's business, financial condition and operating results. The words "project," "believe," "estimate," "expect," "plan", "objective" and other similar expressions, when referring to the Company, are used to identify forward-looking statements. Statements related to the possible outcome of legal and administrative proceedings, implementation of operational and financing strategies and investment plans, guidance on future operations, the objective of expanding its efforts to achieve the sustainable macro objectives disclosed by the Company, as well as factors or trends that affect the financial condition, liquidity or operating results of the Company are examples of forward-looking statements. Such statements reflect the current views of the Company's management and are subject to various risks and uncertainties, many of which are beyond the Company's control. There is no guarantee that the events, trends or expected results will actually occur. The statements are based on various assumptions and factors, including, but not limited to, general economic and market conditions, industry conditions and operating factors, availability, development and financial access to new technologies. Any change in these assumptions or factors, including the projected impact from the joint venture and its development of technologies, from the geological event in Alagoas and related legal procedures and the unprecedented impact on businesses, employees, service providers, shareholders, investors and other stakeholders of the Company could cause effective results to differ significantly from current expectations. For a comprehensive description of the risks and other factors that could impact any forward-looking statements in this document, especially the factors discussed in the sections, see the reports filed with the Brazilian Securities and Exchange Commission (CVM). This Material Fact does not constitute any offer of securities for sale in Brazil. No securities may be offered or sold in Brazil without being registered or exempted from registration, and any public offer of securities carried out in Brazil must be made through a prospectus, which would be made available by Braskem and contain detailed information on Braskem and its management, as well as its financial statements.



PRIVILEGED & CONFIDENTIAL – FOR DISCUSSION PURPOSES ONLY

CONFIDENTIAL SETTLEMENT COMMUNICATION SUBJECT TO FRE 408 AND ITS EQUIVALENTS

PROJECT CATALYST

Cleansing Materials

Disclaimer

These materials and the information contained herein (these "Cleansing Materials") were prepared solely to facilitate discussions with certain members of an ad hoc group of creditors (the "Investors") of Braskem S.A. (together with its subsidiaries and affiliates, the "Company") that were subject to confidentiality agreements and were not prepared with a view toward public disclosure. The Cleansing Materials should not be relied upon to make an investment decision with respect to the Company. The Cleansing Materials speak only as of the date when such information was delivered to the Investors or their representatives and should not be regarded as an indication that the Company or any third party considers the Cleansing Materials to be material non-public information or a reliable prediction of future events, and the Cleansing Materials should not be relied upon as such. Neither the Company nor any third party makes any representation regarding the accuracy or completeness of the Cleansing Materials, whether when first delivered to the Investors or their representatives, as of the date hereof or any other past or future date. Any forward-looking statements are based on current assumptions and expectations and involve risks and uncertainties.

The Cleansing Materials include certain values for illustrative purposes only, and such values are not the result of, and do not represent, actual valuations, estimates, forecasts or projections of the Company or any third party and should not be relied upon as such. Actual values or results may differ materially from those expressed or implied in these Cleansing Materials. Neither the Company, its advisors nor any third party makes any representation to any person regarding the accuracy or completeness of any Cleansing Materials or undertakes any obligation to update the Cleansing Materials to reflect circumstances existing after the date when the Cleansing Materials were prepared or conveyed or to reflect the occurrence of future events, even if any or all of the assumptions underlying the Cleansing Materials become or are shown to be incorrect.

These materials and information contained in the Cleansing Materials are made in connection with potential settlement, compromise, or business resolution discussions. Pursuant to Federal Rule of Evidence 408 and applicable state and foreign law equivalents, this document and any information contained herein shall not be construed as an admission of liability, fault, or wrongdoing, and shall not be admissible as evidence to prove or disprove the validity or amount of any disputed claim or for impeachment purposes in any litigation or proceeding.

These Cleansing Materials do not constitute (and shall not be construed as) an offer to sell, a solicitation of an offer to buy, a commitment to lend, underwrite or provide financing, or a recommendation with respect to any security, loan or transaction.



I Updated Monthly Cash Flow

Disclaimer

This document is delivered pursuant to, and in compliance with, Section 2.1.(iii) of the Negotiation Framework attached as Schedule 1.1.61 to the Extrajudicial Reorganization Plan dated as of August 24, 2026 (the "EJ Plan") jointly filed by Braskem S.A., Braskem Netherlands B.V., Braskem Netherlands Inc. B.V., Braskem Trading & Shipping B.V., Braskem Netherlands Finance B.V. and Braskem America Finance Company (collectively, the "Debtors") and which was adhered to by certain financial creditors of the Debtors representing, on a consolidated basis, 39.6% of the financial debt of the Debtors subject to the EJ Plan (the "Signatory Creditors"). Capitalized terms used and not otherwise defined herein will have the meaning given in the EJ Plan.

This document and the information contained to the recipient pursuant to that certain confidentiality agreements by and between the recipient and Braskem S.A. listed in Annex A hereto (the "NDAs") and constitutes Confidential Information for purpose thereof. By accessing this document and in accordance with Section 4.3 of the Negotiation Framework, the recipient agrees to: (i) treat all the information contained herein as Confidential Information and maintain the confidentiality of all such information; (ii) not reproduce or disclose, in whole or in part, any information contained herein to any person other than as permitted under the relevant NDA; and (iii) comply with any other obligation under the NDA with respect to, or in connection with, such information.

All analysis contained herein has been prepared based upon the Company's internal records. All information in this document is subject to verification, correction or completion without notice. Lazard has not assumed any responsibility for independent verification of any of the information contained herein and it has relied on such information being complete and accurate in all material respects. No representation or warranty, either express or implied, is made by any person as to the accuracy, reliability or completeness of the information presented herein. Neither the Company, Lazard, nor any of their respective subsidiaries, affiliates, directors, officers, agents, employees or advisors accepts any liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this document.

This document does not purport to contain all of the information that a recipient may desire in investigating or deciding to enter into any transaction with, the Company or any subsidiary or affiliate thereof, or otherwise take any course of action, and should not be relied upon to form the basis of, be relied on in connection with, or act as an inducement or recommendation to enter into, any transaction or take any other action whatsoever. This document does not constitute and is not to be construed as an offer to sell or a solicitation to buy, exchange or grant consent to any securities and does not constitute any form of commitment or recommendation on the part of the Company or Lazard or any of their respective subsidiaries, affiliates, associated companies or advisors.

This document should not be regarded by the recipient as a substitute for the exercise of its own judgment to enter into any transaction with the Company or any subsidiary or affiliate thereof or otherwise take any course of action. The risk, merit and suitability of any such transaction should be independently evaluated and any person considering such transaction is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other considerations relating to such transaction prior to entering into any such transaction or otherwise taking any course of action.

By receipt of this document, the recipient acknowledges that it is not relying on the Company or Lazard for tax, accounting, legal or other advice, and that the recipient should receive separate and qualified tax, accounting, legal and other professional advice in connection with any transaction or course of conduct.

Nothing contained herein shall be deemed to be a recommendation from the Company or Lazard to any party to enter into any transaction or to take any course of action. This document provides summary information only and is being delivered solely for informational and discussion purposes. The use of this document for any other purpose is not authorized. This document is not intended to provide a basis for evaluating any transaction, to take any course of action or to be construed as a basis for any other matter.

This document speaks only as of the date hereof, all of which is subject to change, and neither the Company, Lazard nor any other person is under any obligation to update, keep current, bring-down, review or reaffirm the information herein. Under no circumstances should the delivery of this document imply that any information or analyses included in this document would be the same if made as of any other date.

This document includes forward-looking statements. All statements other than statements of historical fact or relating to present facts or current conditions included in this document are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts.

Such forward-looking statements are based on certain assumptions and current expectations and projections about future events and trends that may affect the Company's business and are not guarantees of future performance. Several of those assumptions and expectations are based on, or rely upon, past results or have not necessarily been recently updated or reassessed. Although the Company believes those assumptions are reasonable in light of the available information, they are inherently subject to various risks and uncertainties. Recipients of this document are cautioned that any such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and other unknown factors, including those relating to the operations and business of the Company. These and various other factors may adversely affect the estimates and assumptions on which these forward-looking statements are based, many of which are beyond the Company's control.

The inclusion of forward-looking statements should not be regarded as a representation that any such transaction or event shall be consummated or that the Company will achieve its respective plans, estimates and expectations with respect to such transactions or events. Actual results and capital and other financial conditions may differ materially from those included in these statements due to a variety of factors. In light of the risks and uncertainties described above, the future events and circumstances discussed in this document might not occur and are not guarantees of future performance.

Forward-looking statements speak only as of the date on which they are made. Nothing contained in this document is, or shall be relied upon as, a promise or representation as to the past, present or future. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. RECIPIENTS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS.

This document may include certain financial measures that are not presented in accordance with International Financial Reporting Standards ("IFRS"). These non-IFRS measures are an addition to, and not a substitute for or superior to, measures of financial performance prepared in accordance with an IFRS alternative to net income or any other measures derived in accordance with IFRS. The Company believes that these non-IFRS measures of financial results provide useful supplemental information to creditors about the Company. These non-IFRS financial measures may differ from the calculations of other companies and, as a result, may not be comparable to similarly titled measures presented by other companies.

PRIVILEGED & CONFIDENTIAL – FOR DISCUSSION PURPOSES ONLY
CONFIDENTIAL SETTLEMENT COMMUNICATION SUBJECT TO FRE 408 AND ITS EQUIVALENTS

Updated Monthly Cash Flow – *Standstill*

(In US$ millions, unless otherwise indicated)

	Actual	Projected		
	Sep-26	**Oct-26**	**Nov-26**	**Dec-26**
EBITDA	**118**	**45**	**26**	**(69)**
(±) Working Capital – Operational	115	(131)	137	282
(–) Maintenance Capex	(47)	(72)	(73)	(79)
(–) Alagoas & Penalties	(11)	(26)	(14)	(31)
(±) Others	(113)	(9)	(81)	(11)
(=) Recurring Operating Cash Flow	**62**	**(192)**	**(5)**	**92**
A (±) Working Capital – Financial	192	113	(91)	7
(–) Strategic Capex	(7)	(5)	(5)	(5)
(=) CFADS	**247**	**(83)**	**(101)**	**95**
B (–) Financial Debt – Interest & Amortizations	-	-	-	-
(=) Cash Generation / Consumption	**247**	**(83)**	**(101)**	**95**
BoP Cash Balance	**1,012**	**1,257**	**1,184**	**1,079**
(±) Cash Generation / Consumption	247	(83)	(101)	95
(±) Exchange Rate Variation	(2)	10	(4)	(15)
EoP Cash Balance	**1,257**	**1,184**	**1,079**	**1,159**
(–) Restricted Cash	(167)	(162)	(159)	(158)
Unrestricted Cash Balance	**1,090**	**1,022**	**920**	**1,001**

Source: Braskem.

Considerations

The Cash Flow considers September actuals and projected figures from October through December

A Assumes no payment of letters of credit and considers the ongoing assignment of receivables (True Sale). The commercial credit line with Petrobras is considered in this line

B Assumes no payment of debt service



II Restructuring Proposal – Agreed Terms

Disclaimer

This document (the "Proposal") is delivered in connection with the Extrajudicial Reorganization Plan dated as of August 24, 2026 (the "EJ Plan") jointly filed by Braskem S.A., Braskem Netherlands B.V., Braskem Netherlands Inc. B.V., Braskem Trading & Shipping B.V., Braskem Netherlands Finance B.V. and Braskem America Finance Company (collectively, the "Debtors") and which, as of the date hereof, has been adhered to by certain financial creditors of the Debtors representing, on a consolidated basis, 40.3% of the financial debt of the Debtors subject to the EJ Plan (the "Signatory Creditors"). Capitalized terms used and not otherwise defined herein will have the meaning given in the EJ Plan.

This Proposal contains a non-binding summary of the indicative principal commercial terms and conditions of the Updated Plan. This Proposal does not constitute an offer or a commitment by any Debtor or any Main Shareholder to enter into or otherwise support, as applicable, an Updated Plan in the terms set forth herein and may be subject to changes. The final terms and conditions of the Updated Plan, if and when agreed between the relevant parties, are contingent upon the approval of each Debtor and each Main Shareholder, in accordance with governance requirements and procedures, as well as being contingent upon obtaining and complying with any additional approvals, authorizations and requirements under applicable law and subject to further review of corporate, tax and accounting matters. None of the terms and conditions set forth herein shall be binding upon or enforceable against the Debtors except until such time any such terms and conditions are set forth in the Updated Plan that is duly confirmed by the applicable court and the definitive binding agreements implementing such terms and conditions.

Pursuant to Section 2.7.1 of the EJ Plan, neither this Proposal, nor any other proposal made, resolution adopted in respect of proposals made by the Debtors, or agreement reached by the Debtors and the Signatory Creditors party to the Negotiation Framework in relation to matters that directly affect the Main Shareholders (including, without limitation, commitments, the form and structure of capital contributions, dilution levels and parameters, and the terms and conditions for the conversion of debt into equity) shall be binding upon or enforceable against the Main Shareholders unless expressly consented to in writing by the Main Shareholders in accordance with their applicable corporate governance rules.

This Proposal is being delivered to the recipient pursuant to that certain confidentiality agreements by and between the recipient and Braskem S.A. listed in Annex B hereto (the "NDAs") and constitutes Confidential Information for purpose thereof. By accessing this Proposal and in accordance with Section 4.3 of the Negotiation Framework, the recipient agrees to: (i) treat all the information contained herein as Confidential Information and maintain the confidentiality of all such information; (ii) not reproduce or disclose, in whole or in part, any information contained herein to any person other than as permitted under the relevant NDA; and (iii) comply with any other obligation under the NDA with respect to, or in connection with, such information.

This Proposal has been prepared by Lazard Assessoria Financeira Ltda ("Lazard"), Makalu Partners ("Makalu"), Cleary Gottlieb Steen & Hamilton LLP ("CGSH") and Emunhoz Advogados ("EMunhoz" and, together with Lazard, Makalu and CGSH, the "Debtors Advisors") on behalf of the Debtors for delivery to Houlihan Lokey Capital, Inc., Davis Polk & Wardwell LLP, Pinheiro Guimarães Advogados and the Signatory Creditors. The Debtors Advisors prepared this Proposal based on information that is publicly available and/or provided by the Debtors. The Debtors Advisors have relied upon the accuracy and completeness of such information and have not independently verified it.

Neither the Debtors Advisors nor the Debtors make any representation or warranty, express or implied, as to the accuracy or completeness of this Proposal. Each recipient must conduct its own independent investigation and analysis and may not rely on this Proposal or any statements by the Debtors Advisors or the Debtors as the basis for any investment, credit, legal, tax, accounting or other decision.

This Proposal contains forward-looking statements, including projections, forecasts, estimates, and other statements regarding future events, financial performance, business strategies, and anticipated results. These forward-looking statements are based on current expectations, assumptions, and estimates of the Debtors that are subject to significant business, economic, regulatory, and competitive uncertainties, many of which are beyond the Debtors' control. Actual results may differ materially from those expressed or implied in such forward-looking statements. No representation or warranty is made that any forward-looking statement will be achieved or will prove to be correct. Recipients are cautioned not to place undue reliance on any forward-looking statements contained herein.

This Proposal is being provided in connection with potential settlement, compromise, or business resolution discussions. Pursuant to Federal Rule of Evidence 408 and applicable equivalent laws and regulations of any state or other country or jurisdiction (including Brazil and Netherlands), this Proposal and any information contained herein shall not be construed as an admission of liability, fault, or wrongdoing, and shall not be admissible as evidence to prove or disprove the validity or amount of any disputed claim or for impeachment purposes in any litigation or proceeding. This Proposal is provided for negotiation and discussion purposes only.

Restructuring Proposal | Agreed Terms (11/23) (1/2)

		Agreed Terms
General	Structure	• Restructuring to be achieved through a combination of (i) an equity commitment backstopped by the Main Shareholders or third parties and (ii) debt-to-equity conversion or discount – Transaction to be implemented on a "day-one" basis: both debt-to equity conversion and shareholder equity contribution to close concurrently with the closing of the Equity Rights Offering
	Commercial Credit Line	• Commercial Credit Line to be maintained on its current terms through December 2031 – Amount: R$2,350 million – Outstanding balance to be fully repaid at maturity – Company to explore refinancing alternatives for the facility on a best-efforts basis, as market conditions allow, with the flexibility to fully or partially refinance the facility at any time
Treatment of Claims	Overview	• Three options (Option A, Option B and Option C) available to all Subject Claims • Reduction of total indebtedness by up to ~US$3.6 billion, through a combination of: – Option A debt-to-equity conversion – Option B discount • Criteria for election TBD; provided Option C treatment shall be the default treatment unless creditors expressly elect another option
	Option A	• Open to all holders of Subject Claims; those that elect Option A receive their pro rata share of a combination of Secured Takeback Debt and equity (Debt-to-Equity Conversion): – **Debt-to-Equity Conversion** • Amount: Up to US$3.6 billion (assuming no Option B or Option C election); to be adjusted pro rata for actual Option B and Option C elections ○ To be reduced on a dollar-for-dollar basis for each (i) dollar of discount captured on account of Option B (i.e., 30% of each claim) and (ii) dollar of claims that elect (whether or not by default) Option C • Conversion: mandatory and in full at closing, simultaneously with the Equity Rights Offering • Debt Conversion Price: criteria to be defined – **Secured Takeback Debt** • <u>Note:</u> treatment across existing debt instruments, including term and rate, remains subject to further discussion among the parties • Amount: Remaining electing claims (par plus accrued interest at rates of existing instruments up to restructuring implementation date less debt-to-equity conversion amount) • Maturity: Secured Takeback Debt to be allocated among different series, along an amortization schedule to be mutually agreed; no maturity or amortization of any series of Secured Takeback Debt before 2031 ○ Allocation of existing claims among different series to be negotiated between Company and creditors ○ Each series to be callable at any time at par (i.e., Company may, at any time, prepay the outstanding indebtedness, in whole or in part, without incurring any prepayment fees, premiums, penalties, or other additional charges) • Interest Rate: weighted average interest rate starting at 10.5% p.a., to be reduced subject to the Company achieving certain ratings in accordance with Annex A – mechanics TBD ○ 100% PIK toggle through December 2028 at Company's discretion, subject to a 200bps PIK premium • Collateral: all available assets and equity outside Brazil (subject to other liens and restrictions; to be negotiated in definitive documentation); mortgage / pledge (or similar security) over certain asset(s) in Brazil to be agreed • Cash Sweep: annual excess cash sweep of all cash above US$1.5 billion – mechanics TBD ○ Calculation to exclude proceeds from the Equity Rights Offering for a period TBD from the date such proceeds are received by the Company
	Option B	• Open to all holders of Subject Claims; those that elect Option B receive Secured Takeback Debt in amount equal to 70% of electing claims (i.e., 30% discount), on terms identical to and pari passu with Option A Secured Takeback Debt
	Option C	• Open to all holders of Subject Claims; those that elect Option C receive new 2060 1% PIK takeback debt

Restructuring Proposal | Agreed Terms (11/23) (2/2)

		Agreed Terms
Equity Rights Offering	Amount & Backstop	• At closing, the Company will carry out a capital increase ("Equity Rights Offering") open to all current shareholders and third parties, on the following terms: – **Amount:** follow-on of US$2.25 billion, of which US$1.3 billion will be backstopped by the Main Shareholders or third parties, with commitment provided at the time of the Updated Plan – **Backstop Parties:** any third party (other than the Main Shareholders) that may provide backstop commitment shall be subject to creditor approval prior to plan approval
	Pricing	• 20% discount to the Debt Conversion Price, applicable to all participants subscribing with new money, including current shareholders exercising pre-emptive or priority rights pursuant to articles 170, §1, and 171 of Law No. 6,404/76
	Timing & Structure	• **Timing:** simultaneously with the Debt-to-Equity Conversion • **Implementation and Structure:** to be designed in a manner satisfactory to the shareholders, creditors and the Company, pursuant to the current Shareholders Agreement
Others	Braskem Idesa & Transforma Rio	• **Braskem Idesa:** implementation of the transaction authorized under the Updated Plan • **Strategic investments related to the Transforma Rio project and any other strategic capex (above threshold TBD):** conditional upon acceptance by at least 50% of Signatory Creditors until closing, and then at least 50% of Secured Takeback Debtholders following closing
	Cash Sweep & Asset Sales	• **Cash Sweep:** as set forth in Secured Takeback Debt terms • **Asset Sales:** net proceeds from any asset sale will be applied in accordance with the Cash Sweep mechanism described herein (i.e., subject to the minimum cash balance of US$1.5 billion); provided that, while the ordinary Cash Sweep is measured and applied annually, net proceeds from any asset sale will be subject to the Cash Sweep mechanism on an extraordinary basis, following receipt of the proceeds by the Company – mechanics TBD
	Approvals	• This term sheet is non-exhaustive and definitive documentation will contain additional terms and conditions related to the transaction • The transaction and all such documentation, including structuring of new debt and equity instruments, remain subject to agreement and internal approvals by all relevant parties, including the required creditors and the Debtors and Main Shareholders, in accordance with such parties' applicable governance requirements and procedures

Annex A

Rating	Weighted Average Interest Rate
CCC+ or below	10.50%
B-	10.00%
B	9.50%
B+ or above	9.00%